Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer
Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer
Active, not recruiting · NCT03016338 · Registry updated 2026-06-23Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder | Active, not recruiting | Phase 2 | 2026-06-23 | NCT03016338 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Tesaro, Inc. | 16 |
| University Health Network, Toronto | 417 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cancer Centre of Southeastern Ontario at Kingston | Kingston | Canada | 3 |
| Juravinski Cancer Centre | Hamilton | Canada | 24 |
| London Regional Cancer Centre | London | Canada | 2 |
| McGill University Health Centre - Glen Site | Montreal | Canada | 1 |
| Princess Margaret Cancer Centre | Toronto | Canada | 2 |
| Sunnybrook Research Institute, Sunnybrook Health Sciences Centre | Toronto | Canada | 1 |
| Tom Baker Cancer Centre | Calgary | Canada | 29 |